Data Sheet (Cat.No.T7207)

TargetMol

FK 3311

Chemical Properties



CAS No. : 116686-15-8

Formula: C15H13F2NO4S

Molecular Weight: 341.33

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	FK 3311 (COX-2 Inhibitor V) is an orally available, cell-permeable sulfonanilide that functions as a COX-2 inhibitor and non-steroidal anti-inflammatory drug (NSAID).
Targets(IC50)	COX
In vivo	Survival rate was significantly better (p <0.05) and serum GOT levels 30 min after reperfusion were significantly lower (p <0.05) in the FK 3311(FK) high-dose group compared to the other two groups. Four hours after reperfusion, GPT levels and liver tissue flow were significantly (p <0.05) better in the FK high-dose group compared to the control. Both 30 min and 4 hr after reperfusion, serum TxB(2) levels were significantly lower in the FK high-dose group compared to the control (p <0.05)[1].
Animal Research	Inbred male Lewis rats weighing 200-260 g were used. The donor liver was perfused with cold University of Wisconsin (UW) solution and then stored in the same solution at 4 degrees C for 18 hr. After the preservation period, orthotopic liver transplantation was performed. Animals were divided into three groups: the control group; the FK low-dose group (1 mg/kg FK3311 i.v. 20 min before reperfusion); and the FK high-dose group (3 mg/kg FK3311. 20 min before reperfusion). Survival rate, serum GOT and GPT levels, liver tissue blood flow, and serum thromboxane B(2) (TxB(2)) levels were compared among groups[1].

Solubility Information

Solubility	DMSO: 100 mg/mL (292.97 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (11.72 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9297 mL	14.6486 mL	29.2972 mL
5 mM	0.5859 mL	2.9297 mL	5.8594 mL
10 mM	0.293 mL	1.4649 mL	2.9297 mL
50 mM	0.0586 mL	0.293 mL	0.5859 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Oshima K , Yabata Y , Yoshinari D , et al. The Effects of Cyclooxygenase (COX)-2 Inhibition on Ischemia-Reperfusion Injury in Liver Transplantation[J]. Journal of Investigative Surgery, 2009, 22(4):239-245.